Related references
Note: Only part of the references are listed.In vitro Susceptibility of Leishmania donovani to Miltefosine in Indian Visceral Leishmaniasis
Vijay Kumar Prajapati et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2013)
Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance
Suman Rijal et al.
CLINICAL INFECTIOUS DISEASES (2013)
Leishmaniasis: an update of current pharmacotherapy
Shyam Sundar et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
Shyam Sundar et al.
CLINICAL INFECTIOUS DISEASES (2012)
Visceral Leishmaniasis
Johan van Griensven et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2012)
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Jorge Alvar et al.
PLOS ONE (2012)
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
Ahmed Musa et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh
Mahmudur Rahman et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Liposomal Amphotericin B for Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients: 2-Year Treatment Outcomes in Bihar, India
Prabhat K. Sinha et al.
CLINICAL INFECTIOUS DISEASES (2011)
Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV Prevalence
Koert Ritmeijer et al.
CLINICAL INFECTIOUS DISEASES (2011)
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar et al.
LANCET (2011)
Ambisome plus miltefosine for Indian patients with kala-azar
Shyam Sundar et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2011)
Single-dose liposomal amphotericin B (AmBisome®) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
Tansy Edwards et al.
TRIALS (2011)
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
Raymond Omollo et al.
TRIALS (2011)
Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
Prabhat K. Sinha et al.
JOURNAL OF TROPICAL MEDICINE (2011)
Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India
Prabhat K. Sinha et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2010)
Quality and Strength of Evidence of the Infectious Diseases Society of America Clinical Practice Guidelines
Abdur Rahman Khan et al.
CLINICAL INFECTIOUS DISEASES (2010)
Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure - a case report and brief review of the literature
Jan Rybniker et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Amphotericin B Therapy in Children with Visceral Leishmaniasis: Daily vs. Alternate Day, a Randomized Trial
Utpal Kant Singh et al.
JOURNAL OF TROPICAL PEDIATRICS (2010)
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection
Workagegnehu Hailu et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2010)
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
Ahmed M. Musa et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
Asrat Hailu et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Pediatric Visceral Leishmaniasis in Albania: A Retrospective Analysis of 1,210 Consecutive Hospitalized Patients (1995-2009)
Raida Petrela et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Short-Course Paromomycin Treatment of Visceral Leishmaniasis in India: 14-Day vs 21-Day Treatment
Shyam Sundar et al.
CLINICAL INFECTIOUS DISEASES (2009)
Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009
E. Rosenthal et al.
MEDECINE ET MALADIES INFECTIEUSES (2009)
TWO CASES OF VISCERAL LEISHMANIASIS IN COLOMBIA RESISTANT TO MEGLUMINE ANTIMONIAL TREATMENT
Ivan Dario Velez et al.
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO (2009)
Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda
Y. Mueller et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2008)
New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine
Shyam Sundar et al.
CLINICAL INFECTIOUS DISEASES (2008)
The relationship between leishmaniasis and AIDS: the second 10 years
Jorge Alvar et al.
CLINICAL MICROBIOLOGY REVIEWS (2008)
Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients
Jesus Troya et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2008)
Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients
Nuno Marques et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2008)
Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar
S. Sundar et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2008)
Drug regimens for visceral leishmaniasis in Mediterranean countries
Luigi Gradoni et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2008)
Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
I. Molina et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis
Sujit Kumar Bhattacharya et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Injectable paromomycin for visceral leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Unresponsiveness to AmBisome in some Sudanese patients with kata-azar
Marius Mueller et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2007)
Oral miltefosine for the treatment of Indian visceral leishmaniasis
Shyam Sundar et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2006)
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection
K Ritmeijer et al.
CLINICAL INFECTIOUS DISEASES (2006)
Leishmania-HIV co-infection: An emerging problem in India
Naresh S. Redhu et al.
AIDS (2006)
Mechanisms of experimental resistance of Leishmania to miltefosine:: Implications for clinical use
F. Javier Perez-Victoria et al.
DRUG RESISTANCE UPDATES (2006)
Drug resistance in leishmaniasis
SL Croft et al.
CLINICAL MICROBIOLOGY REVIEWS (2006)
First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France
P Minodier et al.
ARCHIVES DE PEDIATRIE (2005)
Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
DA Kafetzis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis
CP Thakur et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2004)
Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
R López-Vélez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations
S Sundar et al.
CLINICAL INFECTIOUS DISEASES (2004)
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India
SK Bhattacharya et al.
CLINICAL INFECTIOUS DISEASES (2004)
An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in northeast Brazil
SMB Jeronimo et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2004)
Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: A multicenter study
S Sundar et al.
CLINICAL INFECTIOUS DISEASES (2003)
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV:: a randomized pilot study
F Laguna et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug
FJ Pérez-Victoria et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis
V Syriopoulou et al.
CLINICAL INFECTIOUS DISEASES (2003)
Visceral leishmaniasis and HIV coinfection in Bihar, India
PK Sinha et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
Advances in the treatment of leishmaniasis
S Sundar et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2002)
Oral miltefosine for Indian visceral leishmaniasis
S Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
K Ritmeijer et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2001)
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial
S Sundar et al.
BRITISH MEDICAL JOURNAL (2001)
HIV-associated visceral leishmaniasis
V Pintado et al.
CLINICAL MICROBIOLOGY AND INFECTION (2001)
A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study
CP Thakur
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2001)
Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy
J Berenguer et al.
AIDS (2000)
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis
CP Thakur et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2000)
Visceral leishmaniasis in children in South France.
P Minodier et al.
ARCHIVES DE PEDIATRIE (2000)
A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
H Veeken et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2000)
Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
V Soriano et al.
AIDS (2000)
Share Paper
